Mycochlea rubra and application thereof
By providing Plectosphaerella oligotrophica with high β-glucosidase production capacity, the challenge of β-glucosidase in industrial production and drug conversion is solved, and the conversion of ginsenosides Rb1 and Rg1 into rare ginsenosides CK is achieved. and the efficient method of Rh1 enhances the medicinal value.
Patent Information
- Application Number
- CN202410956172.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-17
- Publication Date
- 2024-11-22
- Estimated Expiration
- 2044-07-17
AI Technical Summary
In the prior art, β-glucosidase has insufficient efficient sources and difficulties in substrate selection in industrial production and drug conversion, especially in the absence of effective methods for converting ginsenosides to rare ginsenosides CK and Rh1.
A strain of Plectosphaerella oligotrophica (CGMCC No. 41079) was provided. This strain has efficient production of β-glucosidase and can convert ginsenosides Rb1 and Rg1 into rare ginsenosides CK and Rh1. β was prepared by fermentation culture method. -Glucosidase and rare ginsenosides.
It has achieved efficient production of β-glucosidase and rare ginseng saponins, provided the foundation for the development of drugs, health care and beauty products, broke through the bottleneck of traditional β-glucosidase application, and significantly improved the medicinal value.
Smart Images

Figure CN118995430A_ABST
Abstract
Description
Technical Field
[0001] The invention relates to the technical field of microorganisms, and in particular to a tinea cysticercus fungus and application thereof. Background Art
[0002] β-glucosidase can catalyze the hydrolysis reaction of β-glucosidic bonds and convert the glycoside compounds in the substrate into corresponding glucose and corresponding ligands. Due to its high efficiency, specificity and environmental friendliness, it has been widely used in food processing, medical fields, industrial applications and bioenergy fields. Especially in the field of medicine, β-glucosidase can be used to convert glycoside compounds in natural products (such as plant extracts, etc.), thereby changing their physiological activity and medicinal value. Especially in plants, many medicinal ingredients exist in the form of glycoside compounds, and the active ingredients need to be released through the catalytic action of β-glucosidase.
[0003] For example, as a medicinal plant with high medicinal and economic value, ginseng is widely used in traditional Chinese medicine and health care. Ginsenosides are the main active ingredients of ginseng, and more than 90% of ginseng extracts contain PPD (Rb1, Rb2, Rc and Rd) and PPT (Rg1 and Re) type main ginsenosides. In addition to the above-mentioned main ginsenosides (i.e., ginsenosides with a higher content in ginseng and easier to extract), ginseng also contains rare ginsenosides (also known as "minor ginsenosides"). For example, the rare ginsenoside CK has a low content in nature, but has a good therapeutic effect on diseases such as cancer, diabetes, inflammation, allergies, and angiogenesis, and also has a significant effect in anti-aging and other aspects. Ginsenoside CK has better neuroprotective and hepatoprotective effects than other minor ginsenosides, making it have a wide range of application prospects in the fields of medicine and beauty. Because the content of rare ginsenosides in ginseng is low and it is not easy to extract, but it has unique biological activity in pharmacology and other aspects, it has extremely high economic value and application value.
[0004] Although β-glucosidase has broad application prospects in biotechnology and medicine, there are still some problems and challenges in practical applications. The main challenges facing β-glucosidase at present include how to find efficient sources of β-glucosidase to meet the needs of industrial production, and how to use β-glucosidase to convert glycoside compounds in natural products into target compounds with pharmaceutical activity (i.e., finding suitable substrates and reaction conditions).
[0005] Therefore, there is an urgent need to develop new methods and related products that can produce β-glucosidase with the required enzymatic activity in large quantities and efficiently to meet the production and application needs in this field. Summary of the invention
[0006] The purpose of the present invention is to overcome the above-mentioned problems existing in the prior art and provide a tinea cysticola strain and its application. The tinea cysticola strain provided by the present invention has good β-glucosidase production ability, and the β-glucosidase produced by it can also transform ginsenosides, so that the main ginsenosides Rb1, Rg1, etc. are transformed into rare ginsenosides CK and Rh1, laying a foundation for the development and production of derivative products such as medicines, health products, and beauty products.
[0007] In order to achieve the above object, the present invention provides a strain of Plectosphaerella oligotrophica in a first aspect. The deposit number of the strain is CGMCC No.41079.
[0008] The second aspect of the present invention provides a bacterial agent, wherein the active ingredient of the bacterial agent includes the tinea cysticercus fungus described in the first aspect.
[0009] The third aspect of the present invention provides use of the tinea cysticercus described in the first aspect or the bacterial agent described in the second aspect in the preparation of β-glucosidase.
[0010] A fourth aspect of the present invention provides a method for preparing β-glucosidase, the method comprising contacting the tinea cysticercus described in the first aspect or the bacterial agent described in the second aspect with a fermentation substrate, and performing a first fermentation culture.
[0011] The fifth aspect of the present invention provides β-glucosidase prepared according to the method described in the fourth aspect.
[0012] The sixth aspect of the present invention provides use of the tinea cysticercus described in the first aspect or the bacterial agent described in the second aspect in producing rare ginsenoside CK and / or Rh1.
[0013] A seventh aspect of the present invention provides a method for preparing rare ginsenosides, the method comprising:
[0014] (A) contacting the ginsenosides of the ginsenoside group with the tinea cysticercus described in the first aspect or the bacterial agent described in the second aspect, and performing a second fermentation culture, or contacting the ginsenosides of the ginsenoside group with the β-glucosidase described in the fifth aspect to obtain rare ginsenoside CK; and / or,
[0015] (B) contacting the ginsenosides of the ginsenoside group with the tinea cysticercus described in the first aspect or the bacterial agent described in the second aspect and performing a third fermentation culture, or contacting the ginsenosides of the ginsenoside group with the β-glucosidase described in the fifth aspect to obtain the rare ginsenoside Rh1.
[0016] Through the above technical solution, the present invention can at least achieve the following beneficial effects:
[0017] (1) The present invention is the first to isolate tinea cysticercus from rotten wood grown with Poria cocos, and for the first time discovered the ability of strain LB-002 with strong potential for producing β-glucosidase in the strain (through gene annotation, 304 glycoside hydrolase genes were annotated from the strain, of which 11 β-glucosidase genes were annotated. This shows that strain LB-002 has a strong potential for producing β-glucosidase);
[0018] (2) The β-glucosidase produced by the tinea cysticercus LB-002 provided by the present invention shows the ability to dock with ginsenoside Rb1 and Rg1 molecules in molecular docking, and has the ability to convert them into rare ginsenosides CK and Rh1, respectively, which has never been reported in the current research on tinea cysticercus.
[0019] (3) Experimental verification confirmed that the tinea cysticercus fungus LB-002 provided by the present invention does have a good ginsenoside conversion ability, and can convert the main ginsenosides Rb1 and Rg1 into rare ginsenosides CK and Rh1, which has a positive impact and broad application prospects in the development and production of derivative products such as health products, medicines, and beauty products. BRIEF DESCRIPTION OF THE DRAWINGS
[0020] Figure 1 This is a plate screening diagram of aesculin produced by LB-002, a β-glucosidase produced by the tinea cysticercosis fungus;
[0021] Figure 2A , Figure 2B and Figure 2C These are the phylogenetic trees of the tinea cysticercus LB-002 constructed using the neighbor-joining method based on ITS sequence, LSU sequence and β-TUB sequence;
[0022] Figure 3 This is the genome data of the tinea cysticeris LB-002, annotated with the carbohydrate-active enzyme (CAZy) database;
[0023] Figure 4 The 3D molecular virtual docking results of β-glucosidase protein produced by the fungus LB-002 and (A) ginsenoside Rb1 and (B) ginsenoside Rg1;
[0024] Figure 5 This is the TLC test result of ginsenoside converted by β-glucosidase produced by the fungus LB-002;
[0025] Fig. 6A and Figure 6B This is the full scan of the electrospray ionization mass spectrometry of the sample solution of the tinea cysticercus LB-002;
[0026] Figure 7It is the HPLC chromatogram of the sample solution of the tinea cysticercus LB-002 and the mixed standard solution of ginsenoside CK and 20(S)-Rh1 reference substance.
[0027] Biological Deposit
[0028] The tinea cysticercus LB-002 provided by the present invention is classified and named: Plectosphaerella oligotrophica, and has been deposited in the China General Microbiological Culture Collection Center on January 10, 2024, with the address at No. 3, Yard 1, Beichen West Road, Chaoyang District, Beijing, and the deposit number is CGMCC No.41079. DETAILED DESCRIPTION
[0029] The endpoints and any values of the ranges disclosed in this article are not limited to the precise ranges or values, and these ranges or values should be understood to include values close to these ranges or values. For numerical ranges, the endpoint values of each range, the endpoint values of each range and the individual point values, and the individual point values can be combined with each other to obtain one or more new numerical ranges, which should be considered as specifically disclosed in this article.
[0030] In the present invention, the numbers of reagents or operations (for example, "first liquid culture medium", "second liquid culture medium", "first fermentation culture", "second fermentation culture", "first", "second", etc.) are only used to facilitate the distinction between reagents or operations used in different steps or scenarios in the description, and have no limiting effect on the specific reagent components, contents, operating methods, conditions, sequence, etc. involved.
[0031] Plectosphaerella is a type of plant pathogen that may cause plant wilt, root rot and other diseases, but is not pathogenic to humans or animals. At present, Plectosphaerella is mainly used in research on the occurrence and prevention of plant diseases. Although some achievements have been made in the study of Plectosphaerella in terms of some of its mechanisms or prevention and control methods for causing plant diseases, its potential for application in production has not yet been discovered.
[0032] However, the inventors of the present invention accidentally isolated a strain of tinea cysticercus in their research and found that it had good β-glucosidase production capacity, which made the tinea cysticercus, which was originally only a plant pathogen, have the potential to "turn waste into treasure". After further research, the inventors of the present invention also found that the tinea cysticercus can convert the diol group saponins (such as Rb1) and triol group saponins (such as Rg1) with the highest content in ginseng extract into rare ginsenosides CK and Rh1, which has extremely high application value.
[0033] Based on the above findings, the present invention provides a strain of Plectosphaerella oligotrophica in a first aspect. The deposit number of the strain is CGMCC No.41079.
[0034] The second aspect of the present invention provides a bacterial agent, wherein the active ingredient of the bacterial agent includes the tinea cysticercus fungus described in the first aspect.
[0035] In the bacterial agent provided by the present invention, the tinea cysticercus described in the first aspect may be used as the sole active ingredient, or the tinea cysticercus and other bacteria may be used together as a composite active ingredient.
[0036] According to a preferred embodiment of the present invention, the bacterial agent may further contain auxiliary materials. Any auxiliary materials commonly used in the preparation of bacterial agents in the art may be applicable to the present invention, such as bacterial agent carriers (such as culture media, etc.), protective agents (such as freeze-drying protective agents, etc.), buffers, preservatives, etc.
[0037] In the present invention, there is no particular limitation on the specific supply form of the bacterial agent. For example, the bacterial agent can be a liquid bacterial agent or a solid bacterial agent.
[0038] According to some preferred embodiments of the present invention, the bacterial agent may be a liquid bacterial agent. Preferably, the liquid bacterial agent may be provided by the culture solution of the tinea cysticercus provided by the present invention.
[0039] According to some preferred embodiments of the present invention, the bacterial agent may be a solid bacterial agent. Preferably, the solid bacterial agent may be obtained by freeze-drying the culture solution (expansion culture solution) of the tinea cysticercus provided by the present invention.
[0040] The third aspect of the present invention provides use of the tinea cysticercus described in the first aspect or the bacterial agent described in the second aspect in the preparation of β-glucosidase.
[0041] A fourth aspect of the present invention provides a method for preparing β-glucosidase, the method comprising contacting the tinea cysticercus described in the first aspect or the bacterial agent described in the second aspect with a fermentation substrate, and performing a first fermentation culture.
[0042] According to a preferred embodiment of the present invention, the first fermentation culture system comprises a fermentation substrate and the tinea cysticercus described in the first aspect or the bacterial agent described in the second aspect, and the fermentation substrate is provided by the first liquid culture medium.
[0043] Preferably, the initial pH value of the first liquid culture medium is not less than 5, preferably 5.5-6.5. For example, the initial pH value of the first liquid culture medium may be 5.5, 5.6, 5.7, 5.8, 5.9, 6, 6.1, 6.2, 6.3, 6.4, 6.5, or may be a range consisting of any two of the above values, or any intermediate value in the range.
[0044] Preferably, the first liquid culture medium comprises cellulose (as the main fermentation substrate), and preferably the final concentration of cellulose in the first liquid culture medium is not less than 3 g / L, preferably 3-15 g / L. For example, the final concentration of cellulose in the first liquid culture medium can be 3 g / L, 4 g / L, 5 g / L, 6 g / L, 7 g / L, 8 g / L, 9 g / L, 10 g / L, 11 g / L, 12 g / L, 13 g / L, 14 g / L, 15 g / L, or can be a range consisting of any two of the above values, or any intermediate value in the range.
[0045] According to some preferred embodiments of the present invention, the first liquid culture medium further comprises yeast extract and a trace element source. Yeast extract refers to a type of reagent extracted from yeast that can be used for microbial culture and is usually commercially available in the form of yeast extract, yeast powder, etc.
[0046] The trace element source refers to a reagent in the first liquid culture medium that can provide trace elements for the growth of tinea cysticercus and the production of β-glucosidase. Preferably, the trace element source provides at least one element of K, Mg, Na and Fe to the first liquid culture medium.
[0047] Any reagent that can provide the above elements and can be used for culturing tinea cysts can be applied to the present invention, for example, it can be (inorganic or organic) acid, (inorganic or organic) base, (inorganic or organic) salt of the above elements.
[0048] According to some preferred embodiments of the present invention, the trace element source may include at least one of K2HPO4, MgSO4, NaNO3, FeSO4, etc., and hydrates thereof.
[0049] According to a particularly preferred embodiment of the present invention, the first liquid culture medium comprises:
[0050] K2HPO4 0.01-0.3g / L, MgSO4·7H2O 0.1-1g / L, NaNO3 1-5g / L, FeSO4·7H2O 0.01-0.3g / L, yeast extract 0.1-5g / L, cellulose 1-20g / L, pH=5.5-6.5.
[0051] According to a preferred embodiment of the present invention, the temperature of the first fermentation culture is 25-35°C.
[0052] Preferably, the conditions of the first fermentation culture further include: the amount of the tinea cysticercus or the bacterial agent is such that the initial content of the tinea cysticercus in the first fermentation culture system is not less than 10 7 CFU / mL, preferably 10 7 -10 9 CFU / mL; fermentation culture time is not less than 48h, preferably 50-180h. The initial content of tinea cysticercus is not less than 10 7 CFU / mL means that the initial content of tinea cysticercus in the first fermentation culture system is not less than 10 7 CFU / mL level, 1×10 7 CFU / mL, 5×10 7 CFU / mL, 9.9×10 7 CFU / mL and so on are all 10 7 CFU / mL level. That is, in the present invention, the initial content of tinea cysticercus in the first fermentation culture system can be greater than or equal to 1×10 7 CFU / mL to less than 1×10 10 The CFU / mL range.
[0053] For example, in the first fermentation culture system, the initial content of tinea cysticercus can be 1×10 7 CFU / mL, 2×10 7 CFU / mL, 4×10 7 CFU / mL, 6×10 7 CFU / mL, 8×10 7 CFU / mL, 1×10 8 CFU / mL, 2×10 8 CFU / mL, 4×10 8 CFU / mL, 6×10 8 CFU / mL, 8×10 8 CFU / mL, 1×10 9 CFU / mL, 2×10 9 CFU / mL, 4×10 9 CFU / mL, 6×10 9 CFU / mL, 8×10 9 CFU / mL, 9×10 9 CFU / mL, 9.5×10 9 CFU / mL, 9.9×10 9 CFU / mL, or it may be a range consisting of any two of the above values, or any intermediate value in the range.
[0054] For example, the time of the first fermentation culture can be 50 h, 60 h, 70 h, 80 h, 90 h, 100 h, 110 h, 120 h, 130 h, 140 h, 150 h, 160 h, 170 h, or 180 h, or it can be a range consisting of any two of the above values, or any intermediate value in the range.
[0055] Preferably, the first fermentation culture is carried out under shaking conditions, preferably with a shaking speed of 100-150 rpm.
[0056] According to a preferred embodiment of the present invention, the method further comprises the step of separating and obtaining β-glucosidase from the first fermentation culture product after the first fermentation culture is completed. Any method for separating (extracting) β-glucosidase in the art can be applied to the present invention.
[0057] The fifth aspect of the present invention provides β-glucosidase prepared by the method described in the fourth aspect.
[0058] The sixth aspect of the present invention provides use of the tinea cysticercus described in the first aspect or the bacterial agent described in the second aspect in producing rare ginsenoside CK and / or Rh1.
[0059] A seventh aspect of the present invention provides a method for preparing rare ginsenosides, the method comprising:
[0060] (A) contacting the ginsenosides of the ginsenoside group with the tinea cysticola described in the first aspect or the bacterial agent described in the second aspect, and performing a second fermentation culture, or contacting the ginsenosides of the ginsenoside group with the β-glucosidase described in the fifth aspect to obtain rare ginsenoside CK; and / or,
[0061] (B) contacting the ginsenosides of the ginsenoside group with the tinea cysticercus described in the first aspect or the bacterial agent described in the second aspect and performing a third fermentation culture, or contacting the ginsenosides of the ginsenoside group with the β-glucosidase described in the fifth aspect to obtain the rare ginsenoside Rh1.
[0062] According to a preferred embodiment of the present invention, in mode (A), the second fermentation culture system comprises a culture medium and the tinea cysticercus fungus according to claim 1 or the bacterial agent according to claim 2, and the culture medium is a second liquid culture medium.
[0063] Preferably, the second liquid culture medium comprises ginsenosides from the ginsenoside group, and preferably the final concentration of ginsenosides from the ginsenoside group in the second liquid culture medium is not less than 5 g / L, more preferably 5-50 g / L; more preferably, the ginsenosides from the ginsenoside group comprise ginsenoside Rb1.
[0064] More preferably, the second liquid culture medium further comprises yeast extract and a trace element source, and preferably the trace element source provides at least one element of K, Mg, Na and Fe to the second liquid culture medium;
[0065] Any reagent that can provide the above elements and can be used for the culture of tinea cysticercus to convert ginsenosides of the ginsenoside group into rare ginsenoside CK can be applied to the present invention, for example, it can be (inorganic or organic) acid, (inorganic or organic) base, (inorganic or organic) salt, etc. of the above elements.
[0066] According to some preferred embodiments of the present invention, the trace element source may include at least one of K2HPO4, MgSO4, NaNO3, FeSO4, etc., and hydrates thereof.
[0067] According to a preferred embodiment of the present invention, in mode (A), the temperature of the second fermentation culture is 25-32° C. For example, it can be 25° C., 26° C., 27° C., 28° C., 29° C., 30° C., 31° C., 32° C., or a range consisting of any two of the above values, or any intermediate value in the range.
[0068] According to a particularly preferred embodiment of the present invention, the second liquid culture medium comprises:
[0069] K2HPO4 0.01-0.3g / L, MgSO4·7H2O 0.1-1g / L, NaNO3 1-5g / L, FeSO4·7H2O 0.01-0.3g / L, yeast extract 0.1-3g / L, ginsenosides 5-20g / L.
[0070] Preferably, the conditions of the second fermentation culture further include: the amount of the tinea cysticercus or the bacterial agent is such that the initial content of the tinea cysticercus in the second fermentation culture system is not less than 10 7 CFU / mL, preferably 10 7 -10 10 CFU / mL; fermentation culture time is not less than 150h, preferably 200-400h. The initial content of tinea cysticercus is not less than 10 7 CFU / mL means that the initial content of tinea cysticercus in the second fermentation culture system is not less than 10 7 CFU / mL level. 1×10 7 CFU / mL, 5×10 7 CFU / mL, 9.9×10 7 CFU / mL and so on are all 10 7 CFU / mL level. That is, in the present invention, the initial content of tinea cysticercus in the second fermentation culture system can be greater than or equal to 1×107 CFU / mL to less than 1×10 11 The CFU / mL range.
[0071] For example, in the second fermentation culture system, the initial content of tinea cysticercus can be 1×10 7 CFU / mL, 2×10 7 CFU / mL, 4×10 7 CFU / mL, 6×10 7 CFU / mL, 8×10 7 CFU / mL, 1×10 8 CFU / mL, 2×10 8 CFU / mL, 4×10 8 CFU / mL, 6×10 8 CFU / mL, 8×10 8 CFU / mL, 1×10 9 CFU / mL, 2×10 9 CFU / mL, 4×10 9 CFU / mL, 6×10 9 CFU / mL, 8×10 9 CFU / mL, 1×10 10 CFU / mL, 2×10 10 CFU / mL, 4×10 10 CFU / mL, 6×10 10 CFU / mL, 8×10 10 CFU / mL, 9×10 10 CFU / mL, 9.5×10 10 CFU / mL, 9.9×10 10 CFU / mL, or it may be a range consisting of any two of the above values, or any intermediate value in the range.
[0072] For example, the time of the second fermentation culture can be 200 h, 220 h, 240 h, 260 h, 280 h, 300 h, 320 h, 340 h, 360 h, 380 h, or 400 h, or can be a range consisting of any two of the above values, or any intermediate value in the range.
[0073] Preferably, the second fermentation culture is carried out under shaking conditions, preferably with a shaking speed of 100-150 rpm.
[0074] According to a preferred embodiment of the present invention, in mode (A), the method further comprises the step of isolating ginsenoside CK from the second fermentation product after the second fermentation is completed. Any method in the art for isolating ginsenoside CK from a fermentation broth system can be applied to the present invention.
[0075] According to a preferred embodiment of the present invention, in method (A), the conditions for contacting the panaxadiol saponins with β-glucosidase include: temperature 25-35° C., time 10-40 h.
[0076] For example, the temperature at which panaxadiol saponins are contacted with β-glucosidase can be 25°C, 26°C, 27°C, 28°C, 29°C, 30°C, 31°C, 32°C, 33°C, 34°C, or 35°C, or it can be a range consisting of any two of the above values, or any intermediate value in the range.
[0077] For example, the contact time of panaxadiol saponins with β-glucosidase can be 10h, 12h, 14h, 16h, 18h, 20h, 22h, 24h, 26h, 28h, 30h, 32h, 34h, 36h, 38h, 40h, or a range consisting of any two of the above values, or any intermediate value in the range.
[0078] According to a preferred embodiment of the present invention, in mode (B), the third fermentation culture system comprises a culture medium, and the tinea cysticercus fungus or the bacterial agent, and the culture medium is a third liquid culture medium.
[0079] Preferably, the third liquid culture medium includes ginsenosides from the ginsenoside group, and preferably the final concentration of ginsenosides from the ginsenoside group in the third liquid culture medium is not less than 5 g / L, more preferably 5-50 g / L; more preferably, the ginsenosides from the ginsenoside group include ginsenoside Rg1.
[0080] More preferably, the third liquid culture medium further comprises yeast extract and a trace element source, and preferably the trace element source provides at least one element of K, Mg, Na and Fe to the third liquid culture medium.
[0081] Any reagent that can provide the above elements and can be used for the culture of tinea cysticercus to convert ginsenosides of the ginsenoside group into rare ginsenoside CK can be applied to the present invention, for example, it can be (inorganic or organic) acid, (inorganic or organic) base, (inorganic or organic) salt, etc. of the above elements.
[0082] According to some preferred embodiments of the present invention, the trace element source may include at least one of K2HPO4, MgSO4, NaNO3, FeSO4, etc., and hydrates thereof.
[0083] According to a preferred embodiment of the present invention, in mode (B), the temperature of the third fermentation culture is 25-32° C. For example, it can be 25° C., 26° C., 27° C., 28° C., 29° C., 30° C., 31° C., 32° C., or a range consisting of any two of the above values, or any intermediate value in the range.
[0084] According to a particularly preferred embodiment of the present invention, the third liquid culture medium comprises:
[0085] K2HPO4 0.01-0.3g / L, MgSO4·7H2O 0.1-1g / L, NaNO3 1-5g / L, FeSO4·7H2O 0.01-0.3g / L, yeast extract 0.1-3g / L, panaxatriol saponins 5-20g / L.
[0086] Preferably, the conditions for the third fermentation culture also include: the amount of the tinea cysticercus or the bacterial agent is such that the initial content of the tinea cysticercus in the third fermentation culture system is not less than 10 7 CFU / mL, preferably 10 7 -10 10 CFU / mL; fermentation culture time is not less than 150h, preferably 200-400h. The initial content of tinea cysticercus is not less than 10 7 CFU / mL means that the initial content of tinea cysticercus in the third fermentation culture system is not less than 10 7 CFU / mL level. 1×10 7 CFU / mL, 5×10 7 CFU / mL, 9.9×10 7 CFU / mL and so on are all 10 7 CFU / mL level. That is, in the present invention, the initial content of tinea cysticercus in the third fermentation culture system can be greater than or equal to 1×10 7 CFU / mL to less than 1×10 11 The CFU / mL range.
[0087] For example, in the third fermentation culture system, the initial content of tinea cysticercus can be 1×10 7 CFU / mL, 2×10 7 CFU / mL, 4×10 7 CFU / mL, 6×10 7 CFU / mL, 8×10 7 CFU / mL, 1×10 8 CFU / mL, 2×10 8 CFU / mL, 4×10 8 CFU / mL, 6×108 CFU / mL, 8×10 8 CFU / mL, 1×10 9 CFU / mL, 2×10 9 CFU / mL, 4×10 9 CFU / mL, 6×10 9 CFU / mL, 8×10 9 CFU / mL, 1×10 10 CFU / mL, 2×10 10 CFU / mL, 4×10 10 CFU / mL, 6×10 10 CFU / mL, 8×10 10 CFU / mL, 9×10 10 CFU / mL, 9.5×10 10 CFU / mL, 9.9×10 10 CFU / mL, or it may be a range consisting of any two of the above values, or any intermediate value in the range.
[0088] For example, the time of the third fermentation culture may be 200 h, 220 h, 240 h, 260 h, 280 h, 300 h, 320 h, 340 h, 360 h, 380 h, or 400 h, or may be a range consisting of any two of the above values, or any intermediate value in the range.
[0089] Preferably, the third fermentation culture is carried out under shaking conditions, preferably with a shaking speed of 100-150 rpm.
[0090] According to a preferred embodiment of the present invention, in mode (B), the method further comprises the step of isolating ginsenoside Rh1 from the third fermentation product after the third fermentation is completed. Any method in the art for isolating ginsenoside Rh1 from a fermentation broth system can be applied to the present invention.
[0091] According to a preferred embodiment of the present invention, in method (B), the conditions for contacting the panaxatriol saponins with β-glucosidase include: temperature 25-35° C., time 10-40 h.
[0092] For example, the temperature at which panaxatriol saponins are contacted with β-glucosidase can be 25°C, 26°C, 27°C, 28°C, 29°C, 30°C, 31°C, 32°C, 33°C, 34°C, or 35°C, or it can be a range consisting of any two of the above values, or any intermediate value in the range.
[0093] For example, the contact time of panaxatriol saponins with β-glucosidase can be 10h, 12h, 14h, 16h, 18h, 20h, 22h, 24h, 26h, 28h, 30h, 32h, 34h, 36h, 38h, 40h, or it can be a range consisting of any two of the above values, or any intermediate value in the range.
[0094] The present invention will be described in detail below by way of examples. It should be understood that the following examples are only used to further explain and illustrate the content of the present invention by way of example, and are not intended to limit the present invention.
[0095] In the following examples, unless otherwise specified, the reagents or materials used were all commercial products purchased from regular biological or chemical reagent / material suppliers, and the reagents were all analytical grade.
[0096] The (liquid) culture medium formula / source used in the following examples is as follows:
[0097] Panaxadiol saponins (with Rb1 as the main component) and panaxatriol saponins (with Rg1 as the main component) were purchased from Shanghai Standard Standard Technology Service Co., Ltd.
[0098] Rose Bengal culture medium: purchased from Haibo Biotechnology Co., Ltd. (product number HB0237-2).
[0099] Esculin culture medium: esculin 1 g, ferric citrate 0.5 g, NaCl 2 g, MgSO4·7H2O 0.5 g, KH2PO4 1 g, agar 20 g, dilute to 1 L with deionized water, natural pH.
[0100] Fermentation medium: K2HPO4 0.1 g, MgSO4·7H2O 0.5 g, NaNO3 3 g, FeSO4·7H2O 0.1 g, yeast extract 1 g, cellulose powder 5 g, deionized water to 1 L, pH adjusted to 6.
[0101] Potato glucose liquid culture medium: 5g potato powder, 15g glucose, dilute to 1L with deionized water, natural pH.
[0102] After the above culture media are prepared, sterilize them at 121℃ for 20min, cool to room temperature before use or store in a refrigerator. If solid culture medium plates are used, add 20g / L agar powder before sterilization on the basis of preparing liquid culture medium. After sterilization, pour the plates after cooling until they are not hot (about 50℃). After cooling and solidification, the culture plates of the corresponding culture medium are obtained.
[0103] Example 1
[0104] This example is used to illustrate the separation, screening, identification and preservation of the tinea cysticercus LB-002 provided by the present invention.
[0105] 1. Strain Isolation and Purification
[0106] The strains were isolated by three-point inoculation method using Bengal red culture plates, and then purified by streak method (the culture temperature during the separation and purification process was 28°C, the culture time was 5-7 days, and the growth of the colonies on the plates was observed every day during the culture period).
[0107] Using the above method, a fungus was obtained from a sample of rotten wood grown under the cultivation of Poria cocos in Shuangbai County, Chuxiong Yi Autonomous Prefecture, Yunnan Province, and was named LB-002.
[0108] 2. Screening of β-glucosidase-producing strains
[0109] β-glucosidase can hydrolyze aesculin into glucose and aesculin, which can react with Fe in the culture medium. 3+ According to the property of generating black compounds, the strain LB-002 isolated and purified in Experiment 1 and other strains isolated and purified in the same batch were inoculated on aesculin solid culture plate by the spot-grafting method and cultured at 28°C for 7 days.
[0110] After the culture was completed, the color of the culture medium around strain LB-002 turned brown-black ( Figure 1 ), indicating that the strain has the ability to produce β-glucosidase.
[0111] 3. Identification of strains
[0112] The strain LB-002 isolated in Experiment 1 was subjected to ribosomal internal transcribed spacer (ITS) sequencing, ribosomal large subunit (LSU) sequencing and β-Tubulin (β-TUB) gene sequencing to identify its strain. The above sequencing was entrusted to Beijing Qingke Biotechnology (Kunming) Co., Ltd., where the amplification primers used for the ITS sequence were ITS1 (5'-TCCGTAGGTGAACCTGCGG-3', SEQ ID NO: 1) and ITS4 (5'-TCCTCCGCTTATTGATATGC-3', SEQ ID NO: 2), the amplification primers used for the LSU sequence were NL1 (5'-GCATATCAATAAGCGGAGGAAAAG-3', SEQ ID NO: 3) and NL4 (5'-GGTCCGTGTTTCAAGACGG-3', SEQ ID NO: 4), and the amplification primers used for the β-TUB sequence were T1 (5'-AACATGCGTGAGATTGTAAGT-3', SEQ ID NO: 5) and BT2b (5'-ACCCTCAGTGTAGTGACCCTTGGC-3', SEQ ID NO: 6).
[0113] The sequencing results are shown in Table 1. By comparing the sequencing results with the sequences in the NCBI database, the results showed that the ITS gene amplified fragment of strain LB-002 was 99.42% identical to that of Plectosphaerella oligotrophica CGMCC 3.15078, the LSU gene amplified fragment was 100% identical to that of Plectosphaerella oligotrophica CGMCC 3.15078, and the β-TUB gene amplified fragment was 98.28% identical to that of Plectosphaerella oligotrophica LC1990.
[0114] Table 1
[0115]
[0116] The phylogenetic tree was constructed using the neighbor-joining method (see Figure 2A , Figure 2B and Figure 2C ), the results showed that strain LB-002 and the standard control strain of Plectosphaerella were clustered in the same branch.
[0117] In summary, the LB002 strain was determined to be a microorganism of the genus Plectosphaerella in taxonomy. The isolation of Plectosphaerella from rotten wood grown in Poria cocos has never been reported in related studies in this field.
[0118] 4. Strain preservation
[0119] On January 10, 2024, the LB-002 obtained by the above screening was deposited in the China General Microbiological Culture Collection Center, located at No. 3, Yard 1, Beichen West Road, Chaoyang District, Beijing, with the deposit number CGMCC No.41079.
[0120] Example 2
[0121] This example is used to illustrate the results of whole genome sequencing and genome analysis of the tinea cysticeris LB-002 provided by the present invention.
[0122] 1. Genome Sequencing
[0123] The strain LB-002 was inoculated into potato glucose liquid culture medium and cultured at 150 rpm and 300 g for 5 days. The bacteria were collected by centrifugation and the genome of the strain was sequenced using the Illumina second-generation sequencing platform by Shanghai Meiji Biotechnology Co., Ltd.
[0124] 2. Gene prediction
[0125] The sequencing data were assembled de novo using the short sequence assembly software SOAPdenovo2 (http: / / soap.genomics.org.cn / ), fungal gene prediction was performed using Maker2 software, and rRNA and tRNA contained in the genome were predicted using Barrnap 0.4.2 and tRNAscan-SEv1.3.1 software.
[0126] The total genome length of strain LB-002 is 53,325,194 bp, the G+C (%) content is 55.01%, 309 scaffolds were assembled, 15156 coding genes were predicted, the total gene length is 30,560,308 bp, accounting for 57.31% of the genome, and the average length is 2016.38 bp. 564 tRNAs and 74 rRNAs (73 5S rRNAs and 1 18S rRNA) were predicted.
[0127] 3. Gene function annotation
[0128] The predicted coding genes were compared and functionally annotated with the databases COG, GO, KEGG and the carbohydrate active enzyme database (CAZy). The results are as follows:
[0129] The coding genes of the strain LB-002 genome were compared and analyzed in the GOG database, and a total of 8419 coding genes were annotated. A total of 9282 coding genes were annotated in the GO database. A total of 6599 coding genes were annotated to six major metabolic pathways including metabolism, cellular processes, genetic information processing, environmental information processing, and organismal systems in the KEGG database, including 5188 genes for metabolism, 721 genes for carbohydrate metabolism, and 565 genes for amino acid metabolism, respectively.
[0130] The genome data of strain LB-002 was compared and analyzed in the CAZy database, and 712 genes were annotated; among them, glycoside hydrolase (GH) genes were the most numerous (a total of 304 glycoside hydrolase GH genes were annotated. The results are shown in Figure 3 The results show that strain LB-002 has diversity and adaptability in the utilization of carbohydrates. The 304 glycoside hydrolase genes annotated to strain LB-002 belong to 69 families and 4 subfamilies, of which 11 are β-glucosidase genes. The annotation results show that strain LB-002 has a strong potential to produce β-glucosidase.
[0131] Example 3
[0132] This example is used to illustrate the β-glucosidase production capacity of the tinea cysticeris LB-002 provided by the present invention.
[0133] 1. Fermentation enzyme production and crude enzyme solution preparation
[0134] Use an inoculation loop to scrape an appropriate amount of mycelium from the slant culture medium and place it in a 250 mL conical flask containing 50 mL of liquid fermentation medium (the initial content of tinea cysticercus in the culture medium after inoculation is about 1.5 × 10 7 CFU / mL), 30°C, 150 rpm shaking culture for 5 days. After the culture, take 2 mL of the fermentation liquid and centrifuge at 12,000 rpm for 15 minutes. The supernatant obtained is the crude enzyme solution.
[0135] 2. Determination of β-glucosidase activity in crude enzyme solution
[0136] 2.1. Plotting of p-nitrophenol (pNP) standard curve
[0137] Weigh 139 mg of pNP, add distilled water to make up to 100 mL to obtain 0.01 mmol / mL stock solution, and dilute with distilled water to prepare gradient dilution standard solutions with final pNP concentrations of 0 μmol / mL (i.e. pure water), 0.2 μmol / mL, 0.4 μmol / mL, 0.6 μmol / mL, 0.8 μmol / mL, 1 μmol / mL, 1.2 μmol / mL, and 1.4 μmol / mL.
[0138] Take 200 μL of the above standard solution and 2 mL of citric acid-disodium hydrogen phosphate buffer respectively, mix them, add 2 mL of 1 mol / L Na2CO3 solution to mix thoroughly, measure the absorbance at 410 nm with an enzyme reader, and draw a standard curve based on the measured values.
[0139] The standard curve obtained by the above method is y=0.4156x+0.0734, R 2 =0.9992, where x is the pNP concentration (μmol / mL) and y is the absorbance value corresponding to the concentration.
[0140] 2.2. Enzyme activity assay
[0141] Enzyme activity unit (U): The amount of enzyme required to hydrolyze pNPG to generate 1 μmol pNP per minute at 50°C is one enzyme activity unit.
[0142] Take 2mL of citric acid-sodium hydrogen phosphate buffer and 0.5mL of 5mmol / L pNPG solution and add them to the test tube. After preheating in a water bath, add 0.5mL of 50% crude enzyme solution and bathe in a water bath for 30min. Add 2mL of 1mol / L Na2CO3 solution to terminate the reaction. Determine the OD of the reaction solution. 410 (Use the crude enzyme solution inactivated by boiling for 10 min as a blank control, repeat 3 times), and then calculate the enzyme activity of β-glucosidase in the crude enzyme solution according to the standard curve drawn in step 2.1.
[0143] The results showed that the activity of β-glucosidase produced by strain LB-002 was 10.1±0.8 mU / mL.
[0144] Example 4
[0145] This example is used to illustrate the virtual binding analysis results of the β-glucosidase produced by the tinea cysticeris LB-002 provided by the present invention.
[0146] 1. Prediction of the tertiary structure of β-glucosidase protein produced by strain LB-002
[0147] Use the web interface provided by AlphaFold Colab (https: / / colab.research.google.com / github / sokr ypton / ColabFold / blob / main / AlphaFold2.ipynb) to call alphafold2 to predict protein structure, and use the pLDDT (protein local distance difference test) and pTM (predicted TM score) information output by AlphaFol d2 to measure the accuracy and reliability of the predicted protein structure.
[0148] The tertiary structures of the proteins encoded by the 11 β-glucosidase genes obtained by analyzing the genome of the strain LB-002 in Example 2 were predicted, and the structure prediction scores are shown in Table 2.
[0149] Table 2
[0150]
[0151] From the data in Table 2, it can be seen that the predicted pLDDT of the β-glucosidase proteins encoded by the three enzyme genes gene13502, gene04198 and gene11193 are all higher than 80, indicating that the predicted local protein structure is of good quality, but the pTM is low. The predicted pLDDT of the remaining 8 enzyme proteins is higher than 90, indicating that the predicted local protein structure is very accurate, but the pTM of the β-glucosidase proteins encoded by the gene10548 and gene04310 genes is low. The predicted pLDDT and pTM of the other 6 enzyme proteins are higher than 90 and 0.9, respectively, indicating that they have good structural stability and accuracy.
[0152] 2. Docking of β-glucosidase encoded by strain LB-002 gene with ginsenosides Rb1 and Rg1
[0153] The enzyme proteins with predicted pLDDT scores higher than 90 and pTM scores higher than 0.9 were selected as receptors, and the 3D structures of ginsenoside Rb1 and Rg1 molecules were selected as ligands, respectively. Molecular docking studies were performed using AutoDock Vina software.
[0154] The docking results of the β-glucosidase proteins encoded by the six genes with ginsenosides Rb1 and Rg1 are shown in Table 3. The 3D docking schematic diagram is shown in Figure 4 shown.
[0155] Table 3
[0156]
[0157] From the above results, it can be seen that the docking binding energy between the β-glucosidase protein encoded by the β-glucosidase gene of strain LB-002 and ginsenoside Rb1 and Rg1 molecules is lower than -7kcal / mol; among them, the lowest binding energy between the β-glucosidase protein encoded by the gene07544 gene and ginsenoside Rb1 and Rg1 molecules is -9.3kcal / mol.
[0158] The virtual docking results showed that the β-glucosidase protein of strain LB-002 could effectively bind to ginsenosides Rb1 and Rg1, and had the potential to transform the corresponding ginsenosides.
[0159] Through literature comparison, it can be seen that the minimum binding energy of the β-glucosidase encoded by the β-glucosidase gene of the strain LB-002 and the ginsenoside Rb1 molecule docking is generally lower than the binding energy values of the reported β-glucosidase, indicating that the β-glucosidase encoded by the β-glucosidase gene of the tinea cysticercus LB-002 and the ginsenoside Rb1 have higher affinity potential and catalytic conversion potential; in addition, there has been no report on the molecular docking of the β-glucosidase of the tinea cysticercus and the ginsenoside Rg1 in the field.
[0160] Example 5
[0161] This example is used to illustrate the ability of the β-glucosidase produced by the tinea cysticeris LB-002 provided by the present invention to transform ginsenosides.
[0162] In order to verify whether the β-glucosidase produced by strain LB-002 has the actual ability to transform ginsenosides Rb1 and Rg1 into rare ginsenosides CK and 20(S)-Rh1, the enzyme solution after fermentation of the strain was used to transform ginsenosides Rb1 and Rg1, and the transformation products were preliminarily detected by thin layer chromatography (TLC), and then further analyzed by mass spectrometry (MS) and high performance liquid chromatography (HPLC). The specific methods are as follows:
[0163] 1. Inoculation of strains
[0164] Under sterile conditions, use a 0.7 cm diameter puncher to take 3 bacterial cakes and inoculate them into 50 mL of fermentation medium after cooling by burning with the outer flame of an alcohol lamp. The inoculated medium is placed in a constant temperature shaker at 28°C and 150 rpm for 7 days, and the growth status of the microorganisms during the fermentation process is monitored regularly.
[0165] 2. Preparation of crude enzyme solution
[0166] After the culture was completed, the fermentation broth was centrifuged at 12,000 rpm for 15 min, and the supernatant was filtered using a sterile filter (d=0.22 μm) to remove the bacteria and other impurities, and then used for ginsenoside substrate conversion.
[0167] 3. Conversion of Ginsenosides and Sample Processing
[0168] Take 20 mL of the above enzyme solution and mix it with 2 g of ginsenoside (including 1 g each of diol saponin and triol saponin), place it in a constant temperature shaker at 30°C and 150 rpm for reaction for 24 hours, wherein no enzyme solution is added as a blank control.
[0169] After the reaction is completed, the reaction solution is filtered, 20 mL of 95% ethanol is added to the filter residue, and the residue is soaked for 24 h and filtered again. The filtrate is collected and the volume of the filtrate is fixed to 20 mL again. 10 mL of the filtrate is taken out and concentrated by rotary evaporation, and 1 mL of methanol is accurately drawn with a pipette to dissolve.
[0170] 4. Detection of transformation products by thin layer chromatography
[0171] The sample was spotted on a G60 silica gel plate (5 cm. at the detection turn), blown dry and placed in a developing agent to develop the layer upward. The developing agent was chloroform: methanol: water = 87:13:1 (v / v / v). After the layer was developed, it was blown dry with a hair dryer and placed in an iodine tank to develop the color of the saponin. The unknown saponin product (i.e., the saponin compound contained in the product obtained by the treatment in step 1.3) was compared with a saponin standard of known structure (purchased from Shanghai Shidande Standard Technology Service Co., Ltd.), and the saponin product was preliminarily identified by the ratio transfer value (Rf).
[0172] The unknown saponin product was detected by TLC and compared with the saponin standard of known structure. The results were as follows Figure 5 As shown, band S1 and band S2 correspond to ginsenoside CK and 20(S)-Rh1 standards, respectively. It can be seen that strain LB-002 can convert ginsenosides Rb1 and Rg1 into rare ginsenosides CK and 20(S)-Rh1, respectively.
[0173] 5. Analysis of transformation products by mass spectrometry
[0174] Mass spectrometry conditions: Agilent HPLC1100 MSD / TOF, electrospray ionization (ESI) source, positive or negative ionization mode, mobile phase methanol / water (containing 0.1% formic acid, 80:20, v / v), flow rate 0.2 mL / min, ion source temperature 325°C, drying gas flow rate 7 L / min, fragmentation voltage 150 V.
[0175] Scrape Figure 5 The bands at positions S1, S2 and S3 were dissolved with 1 mL of methanol, and then filtered with a filter (d = 0.45 μm) to remove the silica gel. The filtrate was collected and tested on an instrument.
[0176] The mass spectrum obtained is as follows Fig. 6A and Figure 6B As shown in the figure, ginsenoside CK and 20(S)-Rh1 are expressed as [M+Na] + The ionic form was detected, band S1 [M+Na: 645.43] + , indicating that its molecular formula is C 36 H 62 O8, molecular weight 622.43; band S2 [M+Na: 661.43] + , indicating that its molecular formula is C 36 H 62O9, with a molecular weight of 638.43. Since the molecular formula and molecular weight of bands S1 and S2 matched those of ginsenoside CK and 20(S)-Rh1, the compounds of these two bands were identified as ginsenoside CK and 20(S)-Rh1, respectively.
[0177] 6. Determination of Concentration of Conversion Products by High Performance Liquid Chromatography
[0178] Chromatographic conditions: Agilent HPLC1100, C18 column, 4.6,ent HP; flow rate 1 mL / min; column temperature 30 m; wavelength 203 nm; mobile phase acetonitrile / water; injection volume 20 μL.
[0179] Preparation of mixed standard solution of ginsenoside CK and 20(S)-Rh1 reference substance: accurately weigh 0.50 mg of ginsenoside CK and 20(S)-Rh1 reference substance into the same sample bottle, accurately pipette 1 mL of methanol to dissolve, and shake well to obtain a mixed standard solution of reference substance with a concentration of 0.50 mg / mL.
[0180] Determination: Take the concentrated filtrate dissolved in methanol in step 1.3 and filter it with a 0.45um microporous filter membrane to obtain the sample solution. Determine the peak area of ginsenoside CK and Rh1 under the above chromatographic conditions, and calculate the concentration (mg / mL) of ginsenoside CK and 20(S)-Rh1 in the sample by the single-point quantitative formula.
[0181] The chromatograms of the reference and sample obtained by HPLC test are as follows Figure 7 As shown, the peak areas of the reference substances ginsenoside CK and 20(S)-Rh1 were 4983.68213 and 4338.94727 (mAU*s), respectively. By comparing the chromatogram and retention time of the reference substances, the peak areas of the chromatographic peaks of the conversion products CK and 20(S)-Rh1 were 61344.1 and 48063.6 (mAU*s), respectively. The concentrations of ginsenoside CK and 20(S)-Rh1 were calculated to be 6.15 mg / mL and 5.54 mg / mL, respectively.
[0182] The above experimental results verified that the β-glucosidase produced by the fungus LB-002 can convert ginsenosides Rb1 and Rg1 into rare ginsenosides CK and 20(S)-Rh1, respectively.
[0183] In addition, diol saponins and triol saponins were directly added to the fermentation medium and cultured in the tinea cysticercus LB-002 (the culture medium ingredients are as follows: K2HPO4 0.1g, MgSO4·7H2O 0.5g, NaNO3 3g, FeSO4·7H2O 0.1g, yeast extract 1g, ginsenodiol saponins and ginsenotriol saponins (including Rb1 and Rg1 10g each), deionized water to 1L, natural pH; culture temperature 28°C, 150rpm constant temperature shaker culture for 2 weeks), and the obtained culture solution was detected by mass spectrometry and it was found that the diol saponins and triol saponins originally added in the culture medium were converted into rare ginsenosides CK and 20(S)-Rh1 (mass spectrum and Fig. 6A and 6B This is the first time in the art that a strain of the genus Plectosphaerella has been found to have the ability to convert ginsenosides Rb1 and Rg1 into rare ginsenosides CK and 20(S)-Rh1, respectively.
[0184] The preferred embodiments of the present invention are described in detail above, but the present invention is not limited thereto. Within the technical concept of the present invention, the technical solution of the present invention can be subjected to a variety of simple modifications, including the combination of various technical features in any other suitable manner, and these simple modifications and combinations should also be regarded as the contents disclosed by the present invention and belong to the protection scope of the present invention.
Claims
1. A strain of Plectosphaerella oligotrophica, characterized in that: The deposit number of the tinea cysticercus fungus is CGMCC No.41079.
2. A bacterial agent, characterized in that The active ingredient of the bacterial agent includes the tinea cysticercus fungus described in claim 1.
3. Use of the tinea cysticercus fungus according to claim 1 or the bacterial agent according to claim 2 in the preparation of β-glucosidase.
4. A method for preparing β-glucosidase, characterized in that: The method comprises contacting the tinea cysticercus fungus according to claim 1 or the bacterial agent according to claim 2 with a fermentation substrate, and performing a first fermentation culture.
5. The method according to claim 4, wherein: The first fermentation culture system comprises a fermentation substrate and the tinea cysticercus fungus according to claim 1 or the bacterial agent according to claim 2, wherein the fermentation substrate is provided by a first liquid culture medium; Preferably, the initial pH value of the first liquid culture medium is not less than 5, preferably 5.5-6.5; Preferably, the first liquid culture medium comprises cellulose, and preferably the final concentration of cellulose in the first liquid culture medium is not less than 3 g / L, preferably 3-15 g / L; More preferably, the first liquid culture medium further comprises yeast extract and a trace element source, and preferably the trace element source provides at least one element of K, Mg, Na and Fe to the first liquid culture medium; And / or, the temperature of the first fermentation culture is 25-35°C; Preferably, the conditions of the first fermentation culture further include: the amount of the tinea cysticercus or the bacterial agent is such that the initial content of the tinea cysticercus in the first fermentation culture system is not less than 10 7 CFU / mL, preferably 10 7 -10 9 CFU / mL; fermentation culture time is not less than 48h, preferably 50-180h; Preferably, the first fermentation culture is carried out under shaking conditions, preferably with a shaking speed of 100-150 rpm; And / or, the method further comprises the step of separating β-glucosidase from the first fermentation culture product after the first fermentation culture is completed.
6. β-glucosidase prepared according to the method of claim 4 or 5.
7. Use of the tinea cysticola fungus according to claim 1 or the bacterial agent according to claim 2 in producing rare ginsenoside CK and / or Rh1.
8. A method for preparing rare ginsenosides, characterized in that: The method comprises: (A) contacting the ginsenosides of the tinea cysticola described in claim 1 or the bacterial agent described in claim 2, and performing a second fermentation culture, or contacting the ginsenosides of the ginsenosides of the ginsenosides with the β-glucosidase described in claim 6 to obtain the rare ginsenoside CK; and / or, (B) contacting the ginsenosides of the ginsenoside group with the tinea cysticercus described in claim 1 or the bacterial agent described in claim 2 and performing a third fermentation culture, or contacting the ginsenosides of the ginsenoside group with the β-glucosidase described in claim 6 to obtain the rare ginsenoside Rh1.
9. The method according to claim 8, wherein: In mode (A), the second fermentation culture system includes a culture medium and the tinea cysticercus fungus or the bacterial agent, and the culture medium is a second liquid culture medium; Preferably, the second liquid culture medium includes ginsenosides of the ginsenoside group, preferably the final concentration of ginsenosides of the ginsenoside group in the second liquid culture medium is not less than 5 g / L, more preferably 5-50 g / L; more preferably, the ginsenosides of the ginsenoside group include ginsenoside Rb1; More preferably, the second liquid culture medium further comprises yeast extract and a trace element source, and preferably the trace element source provides at least one element of K, Mg, Na and Fe to the second liquid culture medium; And / or, in mode (A), the temperature of the second fermentation culture is 25-32°C; Preferably, the conditions of the second fermentation culture further include: the amount of the tinea cysticercus or the bacterial agent is such that the initial content of the tinea cysticercus in the second fermentation culture system is not less than 10 7 CFU / mL, preferably 10 7 -10 10 CFU / mL; fermentation culture time is not less than 150h, preferably 200-400h; Preferably, the second fermentation culture is carried out under shaking conditions, preferably with a shaking speed of 100-150 rpm; And / or, in mode (A), the method further comprises the step of isolating ginsenoside CK from the second fermentation culture product after the second fermentation culture is completed; And / or, in method (A), the conditions for contacting the panaxadiol saponins with β-glucosidase include: temperature 25-35° C., time 10-40 h.
10. The method according to claim 8, wherein: In mode (B), the third fermentation culture system includes a culture medium and the tinea cysticercus fungus or the bacterial agent, and the culture medium is a third liquid culture medium; Preferably, the third liquid culture medium includes ginsenosides from the ginsenoside group, and preferably the final concentration of ginsenosides from the ginsenoside group in the third liquid culture medium is not less than 5 g / L, more preferably 5-50 g / L; more preferably, the ginsenosides from the ginsenoside group include ginsenoside Rg1; More preferably, the third liquid culture medium further comprises yeast extract and a trace element source, and preferably the trace element source provides at least one element of K, Mg, Na and Fe to the third liquid culture medium; And / or, the temperature of the third fermentation culture is 25-32°C; Preferably, the conditions for the third fermentation culture also include: the amount of the tinea cysticercus or the bacterial agent is such that the initial content of the tinea cysticercus in the third fermentation culture system is not less than 10 7 CFU / mL, preferably 10 7 -10 10 CFU / mL; fermentation culture time is not less than 150h, preferably 200-400h; Preferably, the third fermentation culture is carried out under shaking conditions, preferably with a shaking speed of 100-150 rpm; And / or, the method further comprises the step of separating ginsenoside Rh1 from the third fermentation culture product after the third fermentation culture is completed; And / or, in method (B), the conditions for contacting the panaxatriol saponins with β-glucosidase include: temperature 25-35° C., time 10-40 h.
Citation Information
Patent Citations
Plant disease controlling composition, plant disease controlling method, and novel microorganism
CA2746046A1
Bacterial strain for preventing myzus persicae
CN103013837A
Method for preparing rare ginsenoside CK from transformed ginsenoside Rb1 and use thereof
CN105296587A
Cucumber sphaerotheca sp.
CN115927002A
Polygalacturonase
JP2012187042A
